Focal rheumatoid inflammation of the dura and leptomeninges was found in an 89-year-old man who was neurologically asymptomatic and had clinically inactive rheumatoid disease. Previous reports of this entity have not stressed that rheumatoid meningitis can be virtually asymptomatic and can develop in persons with apparently quiescent joint disease. The presence of vasculitis of the meningeal or cerebral vessels is associated with symptoms. Intracranial rheumatoid lesions were associated with rheumatoid lesions in other organs, especially the heart and lungs.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Rheumatoid meningitis: a challenging diagnosis for neurologists.
Neurol Sci
January 2025
IRCSS Policlinico San Donato, San Donato Milanese, Italy.
[Clinical analysis of Tolosa-Hunt syndrome].
Zhonghua Yan Ke Za Zhi
January 2025
Department of Ophthalmology, Tianjin Medical University General Hospital, Tianjin300052, China.
Article Synopsis
- The study analyzed clinical features of Tolosa-Hunt syndrome (THS), a type of painful ophthalmoplegia, by collecting data from patients diagnosed at a hospital over four years.
- A total of 35 patients were included, with 18 diagnosed with THS, who typically presented symptoms like pain, ptosis, and MRI abnormalities, alongside various immunological findings.
- Treated with glucocorticoids, most THS patients saw symptom relief within weeks, though some experienced relapses during follow-up.
Assessment of systemic steroid use and its determinants among admitted patients at Debre Berhan University Hakim Gizawu Teaching Hospital.
Sci Rep
December 2024
Department of Midwifery, School of Nursing and Midwifery, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Rational use of steroids is essential in the long term for improving patient safety. Systemic steroids are important in clinical treatment, but if they are misused, they might have negative effects. This study assessed systemic steroid use and its determinants at Debre Berhan University Hakim Gizawu Teaching Hospital (DBUHGTH), Ethiopia.
View Article and Find Full Text PDFIntegrated safety analysis of tofacitinib from Phase 2 and 3 trials of patients with ankylosing spondylitis.
Adv Rheumatol
December 2024
Amsterdam Rheumatology and Immunology Center, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
Objectives: Describe tofacitinib safety from an integrated analysis of randomized controlled trials (RCTs) in patients with ankylosing spondylitis (AS).
Method: Pooled data from Phase 2 (NCT01786668; 04/2013-03/2015)/Phase 3 (NCT03502616; 06/2018-08/2020) RCTs in AS patients were analyzed (3 overlapping cohorts): 16-week placebo-controlled (tofacitinib 5 mg twice daily [BID] [n = 185]; placebo [n = 187]); 48-week only-tofacitinib 5 mg BID (n = 316); 48-week all-tofacitinib (≥ 1 dose of tofacitinib 2, 5, or 10 mg BID; n = 420). Baseline 10-year atherosclerotic cardiovascular disease (ASCVD) risk was determined in patients without history of ASCVD (48-week cohorts).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!